Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma.

< BACK TO ARCHIVE


2022 Apr 04


Cancer Immunol Immunother


http://www.ncbi.nlm.nih.gov/pubmed/35377001?dopt=Abstract

Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma.

Authors

Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma.
Narita Y, Okita Y, Arakawa Y
Cancer Immunol Immunother. 2022 Apr 04.
PMID: 35377001.

Abstract

TAS0313 is a multi-epitope long peptide vaccine targeting several cancer-associated antigens highly expressed in multiple cancer types, including glioblastoma (GBM). This cohort of a Phase 2 part evaluated the efficacy and safety of TAS0313 in patients with GBM.
Read This Paper